Help me understand Takeda logic?

I understand that Takeda is going to launch an "exciting new SSRI" soon. Hmmm...launching an exciting new product in a class that has well established, proven generic agents already dominating the market?

Doesn't this sound like an exact repeat of Edarbi? Oh, we have data showing the unique properties of the new SSRI. This one will be different, besides we have talented sales reps at Takeda to drive this product. Didn't Edarbi also claim that?

Where is Edarbi now?

Is anyone else concerned about this?

It's called DESPARATION!Me-too's is all Takeda can produce,and even if we did launch a novel drug,our history of failed launches would destroy it anyway!